Publications by authors named "T Karasic"
Article Synopsis
- FGFR inhibitors have shown promise in treating FGFR-altered cholangiocarcinoma, but acquired resistance poses a challenge to their effectiveness.
- The study utilized diverse investigative methods, including DNA analysis and tissue biopsies, to explore resistance mechanisms in a cohort of patients.
- Results indicated that a significant number of patients with clinical benefits had specific FGFR2 mutations, but polyclonal resistance was influenced by low drug concentrations and specific mutation types affecting drug efficacy.
Article Synopsis
- Biliary tract cancers (BTC) are aggressive and often diagnosed too late for surgery, making chemotherapy the main treatment option, while radiotherapy (RT) serves as an alternative for certain cases.
- A study at the University of Pennsylvania analyzed 78 patients with unresectable BTC receiving RT, finding that better overall survival (OS) was linked to lower CA19-9 levels and improved albumin-bilirubin (ALBI) grades.
- The developed biomarker model highlights significant variability in OS among patients, indicating that specific risk factors can aid in predicting individual patient outcomes following RT.
Purpose: Systemic therapy with atezolizumab and bevacizumab can extend life for patients with advanced hepatocellular carcinoma (HCC). However, there is substantial variability in response to therapy and overall survival. Although current prognostic models have been validated in HCC, they primarily consider covariates that may be reflective of the severity of the underlying liver disease of patients with HCC.
View Article and Find Full Text PDFWhile high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here we investigate KRAS ctDNA (ctKRAS) variant-specific associations with overall and progression-free survival (OS/PFS) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for patients receiving chemoimmunotherapy ("PRINCE", NCT03214250), and an independent cohort receiving standard of care (SOC) chemotherapy. For PRINCE, higher baseline plasma levels are associated with worse OS for ctKRAS G12D (log-rank p = 0.
View Article and Find Full Text PDFWhat Is This Summary About?: This summary describes the results from a phase 2 study called FOENIXCCA2. The study evaluated treatment with futibatinib in people with a rare form of advanced bile duct cancer called intrahepatic cholangiocarcinoma (or iCCA), where the tumors have changes in the structure of a gene called FGFR2. These changes include FGFR2 gene fusions.
View Article and Find Full Text PDF